Edwards Lifesciences Files Official Comment on CMS' Proposed TAVR National Coverage Determination

Edwards Lifesciences Corporation

, the global leader in the science of heart valves and hemodynamic monitoring, reported that on March 3, 2012, the company filed its official response to the Centers for Medicare & Medicaid Services (

) on its Proposed National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR).